3Daughters to Participate in Women’s Health Panel During the 2024 BIO International Convention in San Diego, CA, June 3-6
23 Mayo 2024 - 4:33PM
3Daughters, Inc., a clinical development company fueling
evolutionary healthcare for women, announced that Mary Beth Cicero,
Co-Founder and CEO, will participate in an expert panel to discuss
the opportunities in Women’s Health and the disparities in funding
along with the actions needed. This panel features some of the top
female executives running Women’s Health companies along with
moderators, Sheila Mikhail, JD, MBA, Board Member, Women's Health
Access Matters and Lucy Pérez, PhD, a Senior Partner at McKinsey
will provide insights on a recent McKinsey report, "Closing the
Women's Health Gap: A $1 Trillion Opportunity to Improve Lives and
Economies".
Details for the panel session are as follows:
Title: Growth Opportunities from Women’s Health Investments
Session Date and Time: June 4, 1:45 p.m. – 2:45 p.m PT
Location: Business Development and Finance 30DE, San Diego
Convention Center
“I am thrilled and honored to participate in this panel on
Women’s Health to address the need for innovation, the
opportunities for products in the space and critical issue of
funding. BIO is dong an incredible job of fostering stronger
investment for Women’s Health by supporting conversations like
these and bringing attention to Women’s Health to drive meaningful
progress for novel treatments for women in the U.S. and globally,”
commented Mary Beth Cicero, Co-founder and CEO of 3Daughters.
3Daughters is raising a Series A of $15M to fund a Phase 1 study
for their game-changing IUD for contraception. Women need improved
and better options for contraception, which is used on average for
thirty years of their lives.
Ms. Cicero and team members will host meetings with
pharmaceutical executives, investors, researchers, and others
throughout the three-day event. To schedule a meeting, please
contact Louis Scotti, Senior Vice President of Business Operations
& Corporate Development.
About 3Daughters™3Daughters is a clinical
development company focused on evolutionary healthcare for women
where cutting-edge research and innovation is desperately needed.
The Company’s technology platform is based on physics and geometry
to deliver targeted therapy to the uterus. The first product,
(3D-001), is a frameless, magnetic, non-hormonal intrauterine
device (IUD) for long-acting contraception that conforms to a
woman’s body. Combined with our unique, patented Slider™ system
(for insertion and retrieval), we will eliminate the most painful
steps in the insertion process as well as the nuisance factor of
strings (needed for removal). 3Daughters’ vision is to solve health
issues for women, particularly significant, and neglected,
problems. 3Daughters plans to radically disrupt the IUD market by
addressing the major adoption barrier — insertion pain. This pain
is associated with all current rigid, plastic T-shape framed IUDs
on the market and prevents women from selecting one of the most
effective forms of birth control.
Visit 3daughtershealth.com for more information.
ContactLouis ScottiSenior Vice President,
Business Operations & Corporate
Developmentlscotti@3daughtershealth.com